JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 176 filers reported holding JUNO THERAPEUTICS INC in Q3 2016. The put-call ratio across all filers is 0.85 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $55,403,000 | -6.0% | 1,212,051 | -7.8% | 0.56% | -16.3% |
| Q3 2017 | $58,943,000 | +21.5% | 1,313,932 | -19.0% | 0.67% | +11.7% |
| Q2 2017 | $48,493,000 | +43.0% | 1,622,380 | +6.2% | 0.60% | +29.9% |
| Q1 2017 | $33,900,000 | +128.0% | 1,527,706 | +93.7% | 0.46% | +96.6% |
| Q4 2016 | $14,867,000 | -43.4% | 788,720 | -9.9% | 0.24% | -50.8% |
| Q3 2016 | $26,273,000 | +29.8% | 875,471 | +66.2% | 0.48% | +16.6% |
| Q2 2016 | $20,247,000 | +8.4% | 526,717 | +7.4% | 0.41% | -1.2% |
| Q1 2016 | $18,681,000 | +10.7% | 490,444 | +27.8% | 0.42% | -10.0% |
| Q4 2015 | $16,873,000 | +8.2% | 383,749 | +0.1% | 0.46% | +8.2% |
| Q3 2015 | $15,598,000 | -12.8% | 383,339 | +14.3% | 0.43% | -2.3% |
| Q2 2015 | $17,879,000 | +0.1% | 335,261 | +13.8% | 0.44% | -5.8% |
| Q1 2015 | $17,866,000 | +50.4% | 294,527 | +29.5% | 0.46% | +51.8% |
| Q4 2014 | $11,880,000 | – | 227,494 | – | 0.30% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Biomark Capital Management Co. LLC | 2,168,601 | $65,080,000 | 86.12% |
| Crestline Management, LP | 17,348,799 | $520,637,000 | 66.02% |
| Omega Fund Management, LLC | 1,229,512 | $36,898,000 | 28.17% |
| SIB LLC | 100,000 | $3,001,000 | 2.42% |
| Clarius Group, LLC | 117,896 | $3,538,000 | 1.65% |
| BB BIOTECH AG | 1,405,000 | $42,164,000 | 1.48% |
| Duquesne Family Office | 493,000 | $14,795,000 | 1.31% |
| First Washington CORP | 65,320 | $1,960,000 | 1.10% |
| PFM Health Sciences, LP | 1,124,285 | $33,740,000 | 0.99% |
| Partner Investment Management, L.P. | 18,376 | $551,000 | 0.82% |